Dr. Sharon Mates, Chair and CEO of Intra-Cellular Therapies, said in a statement, “Johnson & Johnson’s longstanding commitment to neuroscience aligns perfectly with our mission. Together, we can reach even more patients around the world.”
The transaction is expected to close later this year, pending regulatory and stockholder approvals.
Cravath, Swaine & Moore LLP is advising Johnson & Johnson, with Citi serving as its financial adviser. Intra-Cellular Therapies is represented by Davis Polk & Wardwell LLP, while Centerview Partners LLC and Jefferies act as its financial advisers.
The Cravath team includes partners Robert I. Townsend III, Ting S. Chen, and Jin-Kyu Baek. Davis Polk’s team includes partners Michael Davis and Lee Hochbaum. Skadden, Arps, Slate, Meagher & Flom LLP is advising Centerview and Jefferies.
